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Abstract
Background: Thrombospondin-4 (THBS4) is a member of the extracellular calcium-binding protein family and is
involved in cell adhesion and migration. The aim of this study was to evaluate the potential role of deregulation of
THBS4 expression in colorectal carcinogenesis. Of particular interest was the possible silencing of expression by
methylation of the CpG island in the gene promoter.
Methods: Fifty-five sporadic colorectal tumours stratified for the CpG Island Methylator Phenotype (CIMP) were
studied. Immunohistochemical staining of THBS4 protein was assessed in normal and tumour specimens. Relative
levels of THBS4 transcript expression in matched tumours and normal mucosa were also determined by
quantitative RT-PCR. Colony forming ability was examined in 8 cell lines made to overexpress THBS4. Aberrant
promoter hypermethylation was investigated as a possible mechanism of gene disruption using MethyLight.
Methylation was also assessed in the normal colonic tissue of 99 patients, with samples biopsied from four regions
along the length of the colon.
Results: THBS4 expression was significantly lower in tumour tissue than in matched normal tissue.
Immunohistochemical examination demonstrated that THBS4 protein was generally absent from normal epithelial
cells and tumours, but was occasionally expressed at low levels in the cytoplasm towards the luminal surface in
vesicular structures. Forced THBS4 over-expression caused a 50-60% repression of tumour colony growth in all
eight cell lines examined compared to control cell lines. Tumours exhibited significantly higher levels of
methylation than matched normal mucosa, and THBS4 methylation correlated with the CpG island methylator
phenotype. There was a trend towards decreased gene expression in tumours exhibiting high THBS4 methylation,
but the correlation was not significant. THBS4 methylation was detectable in normal mucosal biopsies where it
correlated with increasing patient age and negatively with the occurrence of adenomas elsewhere in the colon.
Conclusions: THBS4 shows increased methylation in colorectal cancer, but this is not strongly associated with
altered gene expression, either because methylation has not always reached a critical level or because other factors
influence THBS4 expression. THBS4 may act as a tumour suppressor gene, demonstrated by its suppression of
tumour colony formation in vitro. THBS4 methylation is detectable in normal colonic mucosa and its level may be a
biomarker for the occurrence of adenomas and carcinoma.
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Thrombospondin-4 (THBS4) is a member of the extracel-
lular calcium-binding protein family. It is a secreted penta-
meric globular protein that forms part of the extracellular
matrix, and functions in calcium binding, cell attachment,
cell migration, cellular proliferation, cytoskeletal organisa-
tion, neurite growth, binding of other extracellular matrix
components and cell to cell interactions [1-6]. THBS4 is
expressed at high levels in the heart and skeletal muscle, is
detected in neuronal tissue in the brain and eye, and also
in the skin, lung, pancreas, T-cells, breast and colon tis-
sues [1,3,5,7,8]. It is a putative tumour suppressor gene,
the hypermethylation of which has been linked to cuta-
neous T-cell lymphoma, breast cancer and colorectal can-
cer (CRC) [6,8,9].
DNA methylation is the addition of a methyl group to
cytosine nucleotide bases via one of the DNA methyl-
transferase enzymes [10]. CpG islands are most com-
monly found within the promoter region of genes,
although they can occur in other coding and non-coding
regions. More than 60% of gene promoters are found
within CpG islands [11]. CpG islands are usually not
methylated regardless of the expression of the gene [7].
However, if these promoter CpG islands become methy-
lated, the associated gene may be permanently silenced,
and this silencing is epigenetically inherited [10,11]. The
promoter region of THBS4 is typical of such a CpG
island that is subject to epigenetic silencing. As a puta-
tive tumour-suppressor gene, methylation of the THBS4
promoter and silencing of its tumour-suppressor func-
tion is potentially pathogenic.
The CpG Island Methylator Phenotype (CIMP) has
been used to describe a subset of colorectal tumours with
a high frequency of methylation in genes known to be
specifically methylated only in neoplasia and not in nor-
mal colon [12,13]. While age-related (Type A) promoter
methylation of some genes is common in both normal
mucosa and neoplastic tissue, there is a subset of genes
whose promoters are only found to be hypermethylated
in CRC (Type C, cancer-related methylation) [12,14].
However, age-related hypermethylation in normal colo-
nic mucosa may contribute to the pre-malignant colorec-
tal field [14,15].
Sporadic colorectal cancer (CRC) can be divided into
clinically relevant subgroups based on gene expression
profiles that reflect pathways of tumour progression.
The traditional pathway accounts for approximately 70%
of all CRC [13]. These are characterised by chromoso-
mal instability, gene mutations and deletions, and are
microsatellite stable (MSS). Adenomas are the precursor
lesions to traditional pathway colorectal cancers [16].
The serrated pathway accounts for approximately 30%
of all sporadic CRC. These are characterised by a
different spectrum of target gene alterations [15,17,18].
Mutations in the BRAF oncogene are common, along
with CIMP [19]. Serrated pathway tumours have high
levels of microsatellite instability (MSI-H), which results
from the hypermethylation and subsequent silencing of
the mismatch repair gene MLH1. Serrated polyps
precede the development of this tumour subgroup [15].
The aims of this study were to evaluate the deregula-
tion of THBS4 in a series of colorectal cancers, to exam-
ine correlations with CIMP, to probe the effect of
forcing THBS4 protein expression in CRC cell lines and
to examine the mechanism of THBS4 deregulation.
Methods
Patient Samples
Quantitative expression (qRTPCR) analysis was per-
formed on 55 matched normal and tumour samples. All
tumour samples collected in a fresh state were macro-
scopically dissected to remove contaminating normal
mucosa. Quantitative methylation (qMSP) analysis was
also conducted on this patient cohort as well as biopsies
of normal mucosa taken during clinically indicated colo-
noscopy in a series of 99 patients. Biopsies were taken
from each of 4 locations within the colon (caecum,
transverse colon, sigmoid colon and rectum). All polyps
were removed and submitted for histology. All patients
gave written, informed consent, and the study was
approved by the RBWH and QIMR Human Research
Ethics Committees. DNA was extracted from tumour
samples using a salt precipitation method as previously
described [20], and from biopsy specimens using a DNA
column method (Qiagen, Hilden, Germany). CIMP sta-
tus was determined in tumours by normalising the
methylation levels of each of the 5 Laird CIMP markers
(CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1) [19]
by the methylation levels observed for the highly methy-
lated ALU gene to generate the PMR, or Percentage of
Methylated Reference. Tumours were classified as
CIMP-negative (CIMP-neg) if 0/5 markers were methy-
lated, CIMP-low (CIMP-L) if 1/5 or 2/5 markers were
methylated, and CIMP-high (CIMP-H) if 3, 4 or 5/5
markers were methylated. The study cohort consisted of
14 CIMP-High, 11 CIMP-Low and 30 CIMP-Negative
tumours.
Expression analysis
Total RNA was extracted using an RNeasy MidiPrep kit
(Qiagen, Hilden, Germany) and cDNA was synthesised
using random hexamers and SUPERSCRIPT III (Invitro-
gen, Carlsbad, California). A Taqman® Gene Expression
Assay (part# 4331182; assay ID Hs00170261_m1 Applied
Biosystems, Carlsbad CA, USA) was performed on
cDNA generating a 96 bp THBS4 product. Gene
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using Taqman® Gene Expression Assay (part# 4331182;
assay ID Hs99999903_m1 Applied Biosystems, Carlsbad
CA, USA) generating a 171 bp product. The qPCR was
performed in duplicate on a RotorGene3000 (Qiagen)
using Absolute QPCR Mix (AB1133A; Integrated
Sciences, NSW, Australia) and cycling of 40 cycles at
60°C annealing. The mathematical model described by
Pffafl was used to determine the expression of THBS4
relative to the housekeeping gene ACTB [21].
THBS4 Immunohistochemistry
THBS4 immunohistochemistry was performed on a subset
of 40 patients. Briefly, fixed tumours were embedded in
paraffin blocks and 0.2 μM sections were cut and mounted
onto Superfrost Plus slides. They were deparaffinized in
xylol and rehydrated by gradient alcohol before a 15 min-
ute incubation with 0.5% hydrogen peroxide in phosphate
buffered saline (PBS) to quench activity of endogenous
peroxidases. After washes in PBS, the first containing
0.05% Triton X-100, sections were incubated in 10% goat
serum and 0.01% acetylated BSA for 60 mins, then incu-
bated overnight at 4°C in mouse anti-human THBS4
monoclonal antibody (MAB2390, R&D Systems, Minnea-
polis, MN) at 1:1500 in PBS/5% goat serum/1%BSA.
Sections were again washed and incubated with rabbit
anti-mouse Envision (Dako, Denmark) for 30 mins. The
chromogenic substrate was 3,3-diaminobenzidine and sec-
tions were counterstained with Meyers’ prior to dehydra-
tion and mounting of slides in Depex. Negative (no
antibody) controls were included in all runs. Once the
normal staining pattern for THBS4 was established, posi-
tive control normal tissue sections were also included in
all runs for consistency.
Colony formation assay
A mammalian expression construct (pcDNA3.1::THBS4)
was designed to examine the effect of over-expressing
THBS4 in CRC cell lines. Briefly, 1 μgo fe i t h e r
pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA) or
pcDNA3.1::THBS4 was transfected into cells using
FuGENE6 (Roche Applied Science, Indianapolis, IN) at a
ratio of 3:1. Three null-expressing cell lines (Lim1215,
SW48 and HT29), one low-expressing cell line (SW480)
and four high-expressing cell lines (DLD1, LS174T,
HCT116 and RKO) were transfected in triplicate at an
initial density of approximately 50%. Cells were allowed
to recover for 48 hrs before application of selective media
at a final concentration of 700 ng/μL G418 (GibcoBRL
Life Technologies, Invitrogen, CA) for 10-14 days. At this
time there were no surviving untransfected control cells,
and transfected colonies were stained with 0.25% crystal
violet/80% methanol. The HT29 transfection was
repeated and individual colonies were expanded to con-
firm THBS4 transcript re-expression.
Methylation Analysis
In order to determine the methylation status of the THBS4
promoter, qMSP was performed for 55 paired normal and
tumour samples, and 13 cell lines. Briefly, 1.5 μgo fD N A
was modified with sodium bisulfite using the EpiTect
Bisulfite kit (Qiagen, Hilden, Germany), diluted 1/8 and
subjected to real time PCR in duplicate on a Rotor-
gene6000 (Corbett Research, QIAGEN, Germany) using
Absolute QPCR Mix (AB1133A; Integrated Sciences,
NSW, Australia) and cycling of 40 cycles at 60°C annealing
(400 nM of F 5′-CGTTGTCGCGGAGTTTAGTA-3′; 600
nM of R 5′-ACGACGACGACGTTAACC-3′;5 0n Mo f
Probe 5′-[DFAM]-ACCTCGATC GACGCCCGAAC
[DBHQ1]). The level of methylation was determined by
normalising the THBS4 methylation levels by the methyla-
tion levels observed for the highly methylated ALU gene
to generate the PMR, or Percentage of Methylated Refer-
ence (400 nM of ALU-F 5′-GGTTAGGTATAGTGGTT-
TATATTTGTAATTT-3′;4 0 0n Mo fA L U - R5 ′-
ATTAACTAAACTAATCTTAAACTCCTAACCT-3′;
100 nM of ALU-Probe [6FAM]-CCTACCTTAAC
CTCCC-[MGBNFQ]; cycling as described for THBS4
qMSP above). Analysis was performed using MethyLight
[22].
Statistical Analysis
The Wilcoxon signed rank test was used to compare
THBS4 expression as well as methylation between the
normal mucosal and tumour pairs. The Kruskal Wallis
test was used to test for a relationship between tumour
THBS4 methylation and CIMP status as well as the dif-
ference in normal mucosal THBS4 methylation in
patients with and without colorectal pathology. A non-
parametric trend test was applied to confirm an ordinal
gradient across multiple groups. THBS4 methylation
within the normal colonoscopic biopsy samples was cal-
culated at each of the four sites sampled, as well as ana-
lysed according to an average proximal (mean of cecum
and transverse colon), distal (mean of sigmoid colon and
rectum) and pancolorectal (mean of all four sites) result.
Correlations were analyzed by the Spearman’sr a n k( r)
coefficient. Distal and proximal levels of methylation
were analyzed by a paired t-test. All tests were performed
using Stata Statistical Software, version 10 [StataCorp].
Results
Expression Analysis
THBS4 expression normalised to ACTB was generally
quite low in both peritumoural normal mucosa and in
tumours (Figure 1). There was significantly higher
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to the tumour. Median THBS4 expression was 0.04 vs.
0.01 respectively (p = 0.0035).
THBS4 Immunohistochemistry
Figures 2A,B &2C show the examples of THBS4 immuno-
histochemical staining. In normal tissue, (Figure 2A and
the right side of 2B) THBS4 protein was absent from the
majority of normal epithelial cells, but was occasionally
expressed in a vesicular pattern. Low levels were seen in
the cytoplasm toward the luminal surface. THBS4 expres-
sion tended to be even lower in tumours compared with
normal mucosa, with the majority of tumours having no
detectable THBS4 expression (left side of Figure 2B, Figure
2C). In general, THBS4 protein was most likely to be seen
at the luminal surface of normal crypts or tumour glands.
However, there was some heterogeneity within the tumour
sections and Figures 2D,E and 2F show some interesting
variations to the general protein localisation in tumour
sections. In Figures 2D and 2E, THBS4 protein seemed to
be significantly up-regulated and actively secreted or pack-
aged in vesicular structures (Figure 2F). These expression
patterns suggest that THBS4 protein may be secreted or
packaged and may give clues as to its function, although
further functional studies are now required to test this
hypothesis. If THBS4 protein is being packaged and
secreted, it is possible that this may be one reason such
low levels are detected in normal mucosa. The low fre-
quency of detectable staining in tumour samples did not
allow meaningful comparison with other molecular ana-
lyses. Immunohistochemical staining was primarily used
to provide novel insight into the cellular distribution of
THBS4 expression patterns.
Colony formation assay
Colony formation was significantly repressed in all eight
cell lines examined following over-expression of THBS4.
We observed that both the number of colonies and
their size were greatly reduced upon forced over-expres-
sion of THBS4. Figure 3 quantifies the THBS4 repres-
sion of colony formation in all cell lines tested. The
reduction in colony formation ranged from 34% to 89%
compared with the vector-only controls. Forced over-
expression of THBS4 in multiple colorectal cancer cell
lines, regardless of their basal THBS4 expression, consis-
tently reduced colony forming ability. This indicates
that high levels of this protein is associated with reduced
tumour cell growth. To confirm that THBS4 transcript
was introduced by transfection with this construct,
HT29 was transfected and 14 individual clones were
expanded. Of these, 8 showed high levels of THBS4
transcript whilst the remaining 6 had negligible
Figure 1 THBS4 expression is higher in normal mucosa than in tumour tissue. While the relative expression of THBS4 was quite low overall,
THBS4 expression was significantly higher in peritumoural normal mucosa than in the tumour tissue. Median expression in normal mucosa was
0.04 vs. 0.01 for tumour tissue (p = 0.0035). Circular and diamond shaped dots represent individual data point for normal and tumours samples,
respectively.
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tal HT29 cells.
Methylation Analysis
Overall, colorectal cancers had significantly higher THBS4
methylation than the matched normals (Figure 4).
The median PMR in normals was 0.06 vs. 2.6 in tumours
(P < 0.0001). Tumours were classified into CIMP sub-
groups using the Laird marker panel [19]. When stratified
by CIMP status, there was no difference in the methylation
of normal mucosa between the different classes of
tumours. However, THBS4 methylation in tumours was
positively correlated with CIMP (Figure 5). Tumour PMRs
showed a progressive increase with increasing level of
Figure 3 Over-expression of THBS4 significantly decreases colony formation in CRC cell lines. Forced over-expression of THBS4
significantly decreases colony formation in colorectal cancer cell lines regardless of their baseline expression levels. The average reduction in
colony formation following THBS4 over-expression was 50-60% compared with vector-only controls. This consistent and significant reduction in
colony forming ability may indicate that high levels of this protein could correlate with reduced tumour cell growth.
Figure 2 The THBS4 protein appears to be secreted. THBS4 protein is not expressed or is expressed at low levels in normal cells, especially
towards the luminal surface. Tumour expression of THBS4 is heterogeneous, with generally no expression but occasional areas of strong
expression and packaging in vesicular structures.
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Page 5 of 10Figure 4 THBS4 methylation is significantly higher in neoplastic tissue compared to adjacent normal tissue. THBS4 methylation was
significantly higher in neoplastic tissues compared to the adjacent normal tissue (p < 0.0001). The median PMR in normal mucosa was 0.06
compared with a PMR of 2.6 in tumour tissue.
Figure 5 THBS4 methylation increases with increasing CIMP methylation. Tumours were stratified according to the Laird classification of
CIMP, separated into CIMP-neg (0/5 markers positive for methylation), CIMP-low (1/5 or 2/5 markers positive for methylation) and CIMP-high
(3, 4 or 5/5 markers methylation positive) categories of methylation. THBS4 methylation was found to positively correlate with CIMP. The greater
the number of Laird markers that were positive for CIMP, the higher the level of THBS4 promoter methylation. The median PMRs were 0.69 for
CIMP-negative tumours, 3.4 for CIMP-L tumours, and 5.8 for CIMP-H tumours (p = 0.033).
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being 0.69, 3.4 for CIMP-L tumours, and 5.8 for CIMP-H
tumours (p = 0.033).
Using a PMR of 10 as a cut off [19], tumours were
separated into THBS4 methylation positive (PMR ≥10)
and THBS4 methylation negative (PMR < 10). THBS4
promoter hypermethylation (PMR ≥10) was observed in
4/30 (13.3%) CIMP-NEG tumours, 4/11 (36.4%) CIMP-L
tumours, and 5/14 (35.7%) CIMP-H tumours. Thus,
while the average tumour PMR correlates well with an
increasing number of markers positive for CIMP, there
were an equal proportion of CIMP-L and CIMP-H
tumours that showed high THBS4 methylation.
Correlation of Expression and Methylation of THBS4
In CRC cell lines, there was no significant correlation
between THBS4 transcript expression when compared
with THBS4 PMR (r = 0.42, p = 0.20) on a continuous
scale (Table 1). There was also no difference in expres-
sion in the colorectal cancer cell lines tested when the
PMR cut-off of ≥10 was used (p = 0.35, data not
shown). However, of the 11 cell lines tested, only 3 had
a PMR of < 10. Tumours were also analysed for THBS4
expression level. Tumours with THBS4 PMR ≥10
appeared to have lower THBS4 expression, but this dif-
ference was not significant, according to the Wilcoxon
Rank-sum (Mann-Whitney) analysis (p = 0.26, data not
shown). Thus, while there was a trend towards lower
THBS4 expression in tumours with a PMR greater than
or equal to 10 having decreased expression, this differ-
ence was not significant. When tumour expression levels
were normalised to matched normal mucosa expression
levels, 44 cancers showed reduced expression greater
than 1.5 fold (average 186.5 fold down-regulation) whilst
15 cancers showed greater than 1.5 fold up-regulation
(average 26.5 fold) and seven tumours did not vary in
expression levels by more than 1.5 fold.
Methylation of THBS4 in Normal Colonic Biopsies
THBS4 methylation was detected within the normal
mucosa in all 99 of the colonoscopy patients with simi-
lar levels of methylation within the proximal and distal
colorectum (median PMR 0.66 vs. 0.65, respectively,
p = 0.66). Additionally, there were no differences in
THBS4 methylation between the sexes, either at indivi-
dual sites or in terms of pancolorectal THBS4 methyla-
tion. There was however, a strong and direct correlation
between patient age and pancolorectal THBS4 methyla-
tion (r = 0.50, p < 0.0001, Figure 6).
THBS4 methylation was lower in the background
mucosa of patients with colorectal adenomas compared
to those with normal colonoscopies. Inclusion of the
peritumoural normal mucosal samples and stratification
by age, revealed a consistent and inverse association
between adenomatous pathology and THBS4 methyla-
tion (Figure 7). Importantly, THBS4 methylation within
the normal colorectal field showed an impressive and
inverse biological gradient with the presence of colorec-
tal pathology, with the lowest levels of THBS4 methyla-
tion within the mucosal field being associated with the
most advanced pathology (Figure 7). This suggested that
THBS4 methylation in the normal mucosa was not
directly implicated in promoting colorectal neoplasia
and could in fact be directly or indirectly protective.
This is supported by our DNA methylation data in
other “type A” genes [23].
Discussion
Thrombospondin-4 is a putative tumour-suppressor gene
that plays an integral role in mediating cellular pro-
cesses such as cell attachment and migration [4]. Classes
of tumour suppressor genes include those involved with
DNA repair, cell growth, cell cycling, cell adhesion, cell
migration, transcriptional regulation and apoptosis [24].
These may be inactivated through gene mutation, chro-
mosomal deletion or methylation [25]. Tumour suppres-
sor genes encode proteins which, upon loss of function,
such as through epigenetic silencing, leads to a selective
growth advantage for neoplastic cells. THBS4 has shown
to be methylated in several tumour types, and this
methylation is associated with transcriptional down-reg-
ulation [6,8,9].
Thrombospondin-4 is expressed at low levels in nor-
mal colonocytes, especially in the cytoplasm towards the
luminal surface. Expression in tumours tends to be even
lower than the levels observed in normal mucosa.
Immunohistochemical localisation of THBS4 confirmed
the absence of protein expression in the majority of
tumours. However, some cancer cells within particular
Table 1 THBS4 expression is not related to its promoter
methylation in CRC cell lines
Cell Line THBS4 Expression THBS4 PMR
DLD1 7.24 93.68
HCT116 7.9 124.41
HT29 0 100.06
LIM1215 0 0
LIM1863 0 0
LISP1 12.92 140.51
LoVo 0.3 14.8
LS174T 7.24 2.23
RKO 6.97 224.29
SW48 0 139.72
SW480 0.89 58.6
There is no correlation between reduced THBS4 expression high THBS4
promoter methylation in CRC cell lines (r = 0.42, p = 0.20).
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Page 7 of 10Figure 6 THBS4 methylation is associated with ageing in normal colorectal mucosa. A strong correlation was observed between THBS4
methylation (presented as the log transformed pancolorectal result) and age in the normal mucosa from the colonoscopy study (r = 0.50,
P < 0.0001). Because of this strong relationship with aging, we have postulated that THBS4 is a Type A (age-related) marker of methylation.
Figure 7 Relationship of THBS4 methylation within the normal mucosa to pathology present elsewhere within the colorectum. THBS4
methylation within the normal mucosa with respect to the pathology present elsewhere within the colorectum was stratified by age (< 50
years, p = 0.018 and > 50 years, p = 0.0001). There was a significant trend evident in both groups p = 0.007 and p < 0.001 for young
colorectum (< 50 yrs) and aged colorectum (> 50 yrs) respectively, indicating a significant inverse relationship between adenomatous pathology
and THBS4 methylation. The lowest levels of THBS4 promoter methylation were associated with the most advanced pathology in both young
and aged colorectal mucosa.
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sion. A subset of tumours did express THBS4 and
evidently secrete the protein, observed as more intense
staining of vesicular structures towards the luminal
surface. Indeed, THBS4 can been readily collected from
culture supernatants of cells expressing THBS4 con-
structs [26], or display prominent ER and Golgi labelling
[3], indicating that it is a secreted protein. While the
secretion of the THBS4 protein may account for the low
levels of staining observed, qPCR also demonstrated that
gene expression is generally quite low. Thrombospondin-
4 expression by qPCR is significantly higher in normal
tissues than in matched tumour samples, supporting the
notion that loss of THBS4 provides a selective growth
advantage to cancer cells.
The forced over-expression of THBS4 in cancer cell
lines significantly suppresses their colony forming abil-
ities and growth, regardless of their baseline THBS4
expression levels. This was demonstrated in vitro for all
8 CRC cell lines tested, each with varying basal levels of
THBS4 expression. A consistent and significant growth
suppression of 50-60% was observed following the
forced over-expression of THBS4. This demonstrates
that a large amount of THBS4 protein correlates with
reduced cell growth, and strengthens the evidence sup-
porting its role as a tumour suppressor gene. Further
experiments are now required to investigate the
mechanism of this reduced growth, which may be a
direct result of THBS4-mediated tumour suppression or
toxicity due to higher than physiologically normal levels
of THBS4 protein.
The Laird methylation marker panel used to deter-
mine CIMP status of colorectal cancers consists of the
CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1
genes [19]. THBS4 methylation in the tumours, as quan-
titatively measured by MethyLight, significantly
increased with the increasing CIMP status of tumours.
The greater the number of CIMP markers that were
positive for methylation (PMR ≥10), the higher the level
of THBS4 methylation, although the same proportion of
CIMP-L and CIMP-H tumours demonstrated high
THBS4 methylation. This suggests that THBS4 methyla-
tion may have a role in progression of CIMP positive
CRC, regardless of level of CIMP.
We postulated that methylation of the THBS4 promo-
ter region would cause reduction in gene expression
level. However, although normal mucosa has signifi-
cantly higher expression than tumour tissue and signifi-
cantly lower methylation than tumour tissue, there was
no statistically significantly correlation between high
promoter methylation and reduced gene expression.
Reduced THBS4 expression levels did not correlate with
a THBS4 PMR of 10 or greater in either cancers or cell
lines. Nevertheless, in another study, methyltransferase
inhibition by 5-azadeoxycytidine in SW48 cells resulted
in reactivation of silenced THBS4 [6]. Thus, it appears
that other factors may control expression of this gene,
a n dt h a tt h em o d e r a t el e v e l so fTHBS4 methylation
observed in our study are not enough to significantly
inhibit gene expression. It is also possible that other
CpG sites within the THBS4 gene promoter that were
not examined in this study are important for regulating
gene expression
The genes methylated in CRC may be characterized as
“type A” (Age-related) genes and “type C” (Cancer-speci-
fic) genes [27]. Generally, “type A” genes are methylated
in both normal and tumour tissue and their degree of
methylation is proportional to the age of the normal
tissue [14,27,28]. The methylation of “type C” genes,
however, is more specific for neoplastic tissue
[14,27-30]. From this study, THBS4 behaved as a “type
A” gene. THBS4 exhibited methylation in both normal
and tumour tissue and displayed a positive correlation
with age. Furthermore, as demonstrated in a recent
study, [23]THBS4 behaved as a “type A” marker with
respect to its association with neoplasia found elsewhere
within the field. Methylation of the THBS4 promoter
was highest in normal mucosa in patients with normal
colonoscopies, and declined progressively as more
advanced pathology was evident (Figure 7).
Conclusions
THBS4 may act as a tumour suppressor gene, evidenced
by the dramatic repression of colony formation upon
forced over-expression in CRC cell lines and its gener-
ally lower expression in cancers compared to normal
mucosa. THBS4 methylation is higher in cancers that
also exhibit the CIMP phenotype, which is demonstrated
by the strong correlation with the Laird panel of methy-
lation markers. However, it appears that methylation has
not reached a critical level where it alters THBS4 gene
expression, or that THBS4 expression is regulated by
factors in addition to promoter hypermethylation.
THBS4 promoter methylation occurs in a manner repre-
sentative of a Type A gene, which is methylated in nor-
mal aged colon as part of the aging process. Additional
studies are required to identify other genes that are
involved in the regulation of THSB4.
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